Neurocrine Biosciences Posts Sizzling Sales Growth in Q2
Neurocrine Biosciences (NASDAQ: NBIX) shareholders should be pleased with the stock so far in 2019. The biotech's share price is up more than 30% year to date. And it reported solid revenue growth in its first-quarter results announced in April.
Anyone wondering if Neurocrine could keep the momentum going got a strong affirmative when the company announced its second-quarter results after the market closed on Monday. It again delivered a solid performance.
Image source: Getty Images.
Quelle Fool.com
